FindTrial
Sign In

HEPATO-RENAL SAFETY AND EXCRETORY DURATION OF HEAVY METALS IN PATIENTS TAKING PROLONGED COURSE OF SIDDHA METALLIC DRUGS FROM NOI NAADAL PERSPECTIVE.

HEPATO-RENAL SAFETY AND EXCRETORY DURATION OF HEAVY METALS IN PATIENTS TAKING PROLONGED COURSE OF SIDDHA METALLIC DRUGS FROM NOI NAADAL PERSPECTIVE.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/06/019496
Enrollment
40
Registered
2019-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M150- Primary generalized (osteo)arthritis

Interventions

Intervention1: NOT APPLICABLE: TWO GROUP AND OBSERVATION Blood and Urine samples only

Sponsors

Ayothidoss Pandithar Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Group A: Patients who are taking metallic drugs for more than two months. Group B : Patients who were taking metallic drugs for 2 months or more with or without break before one year or more.

Exclusion criteria

Exclusion criteria: Patients with hepato renal pathology. Patients with any major illness with altered clinical parameters. Patients underwent or ongoing allopathic treatment for non communicable disease.

Design outcomes

Primary

MeasureTime frame
To infer the parameters used for assessment in both siddha and modern laboratory parameters by comparing the test results during the start and end of the srtudy with condition of the patient with respect to disease.Timepoint: 6 months—

Secondary

MeasureTime frame
To determine the excretory patterns and duration of heavy metals in blood and urine .Timepoint: 6 months—

Countries

India

Contacts

Public ContactDr M Ramamurthy

National Institute of Siddha

ramsnis@gmail.com9443178112

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026